Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 31:3:211.
doi: 10.3389/fimmu.2012.00211. eCollection 2012.

Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity

Affiliations

Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity

Federica Barzaghi et al. Front Immunol. .

Abstract

Immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is a rare monogenic primary immunodeficiency (PID) due to mutations of FOXP3, a key transcription factor for naturally occurring (n) regulatory T (Treg) cells. The dysfunction of Treg cells is the main pathogenic event leading to the multi-organ autoimmunity that characterizes IPEX syndrome, a paradigm of genetically determined PID with autoimmunity. IPEX has a severe early onset and can become rapidly fatal within the first year of life regardless of the type and site of the mutation. The initial presenting symptoms are severe enteritis and/or type-1 diabetes mellitus, alone or in combination with eczema and elevated serum IgE. Other autoimmune symptoms, such as hypothyroidism, cytopenia, hepatitis, nephropathy, arthritis, and alopecia can develop in patients who survive the initial acute phase. The current therapeutic options for IPEX patients are limited. Supportive and replacement therapies combined with pharmacological immunosuppression are required to control symptoms at onset. However, these procedures can allow only a reduction of the clinical manifestations without a permanent control of the disease. The only known effective cure for IPEX syndrome is hematopoietic stem cell transplantation, but it is always limited by the availability of a suitable donor and the lack of specific guidelines for bone marrow transplant in the context of this disease. This review aims to summarize the clinical histories and genomic mutations of the IPEX patients described in the literature to date. We will focus on the clinical and immunological features that allow differential diagnosis of IPEX syndrome and distinguish it from other PID with autoimmunity. The efficacy of the current therapies will be reviewed, and possible innovative approaches, based on the latest highlights of the pathogenesis to treat this severe primary autoimmune disease of childhood, will be discussed.

Keywords: FOXP3; HSCT; IPEX; Treg; autoimmune enteropathy; neonatal diabetes; neonatal eczema.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the FOXP3 gene reporting all the mutations published so far. Annotations refer to both coding sequence and protein, when applicable (www.ncbi.nlm.nih.gov/CCDS, accession number CCDS14323.1). *c543C>T is a polymorphism. E, exon; Color code: orange, N-terminal domain; green, zinc finger domain; blue, leucin-zipper domain; red, forkhead domain.

References

    1. Allan S. E., Alstad A. N., Merindol N., Crellin N. K., Amendola M., Bacchetta R., Naldini L., Roncarolo M. G., Soudeyns H., Levings M. K. (2008). Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. Mol. Ther. 16, 194–20210.1038/sj.mt.6300341 - DOI - PubMed
    1. Allan S. E., Crome S. Q., Crellin N. K., Passerini L., Steiner T. S., Bacchetta R., Roncarolo M. G., Levings M. K. (2007). Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19, 345–35410.1093/intimm/dxm014 - DOI - PubMed
    1. Allan S. E., Passerini L., Bacchetta R., Crellin N., Dai M., Orban P. C., Ziegler S. F., Roncarolo M. G., Levings M. K. (2005). The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J. Clin. Invest. 115, 3276–328410.1172/JCI24685 - DOI - PMC - PubMed
    1. An Y. F., Xu F., Wang M., Zhang Z. Y., Zhao X. D. (2011). Clinical and molecular characteristics of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in China. Scand. J. Immunol. 74, 304–30910.1111/j.1365-3083.2011.02574.x - DOI - PubMed
    1. Bacchetta R., Gambineri E., Roncarolo M. G. (2007). Role of regulatory T cells and FOXP3 in human diseases. J. Allergy Clin. Immunol. 120, 227–235; quiz 236–227.10.1016/j.jaci.2007.06.023 - DOI - PubMed

LinkOut - more resources